Aslan Pharmaceuticals (ASLN +388.7%) skyrockets on news that new pre-clinical data characterizing its ASLAN003 drug as a potential treatment for acute myeloid leukemia was published in the latest Haematologica Journal.
ASLN says the findings “support ASLAN003’s potential as a potent human dihydroorotate dehydrogenase inhibitor and novel target for differentiation therapy with a favorable toxicity profile.”
The company says it recently completed a Phase 2a study of ASLAN003 in acute myeloid leukaemia and is reviewing future development plans.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.